The FDA laid out a “Rare Disease Framework Initiative” aimed at reworking how the agency reviews rare disease therapies, shifting from one-size-fits-all standards toward condition-specific expectations. The plan will run through a process that includes patient and expert input and culminates in a “fit-for-purpose framework” spanning pre-clinical engagement through post-marketing commitments.